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Fig. 1. (A) Chest high-resolution computed tomography showing bilateral ground glass opacities and interlobular septal thickening. (B) Chest high-resolution computed
tomography after corticosteroid treatment, showing resolution of the pulmonary lesions.
choice is systemic corticosteroids.2 Our patient presented clinical
and radiological findings consistent with radiation pneumonitis. It
is important that this complication is  recognized, and it must be
taken into account among patients undergoing hepatic radioem-
bolization.
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Dogmas and Medical Beliefs in COPD
Dogmas y Creencias Médicas Acerca de la EPOC
To the Editor,
Physicians who spend their lives treating patients have always
lived with the social representations of health, disease, and medica-
tion. These social representations are construct images of a  natural
reality and are as old as the disease itself. Based on affective and
cognitive predispositions, and often inhabited by fears, beliefs, and
magical and supernatural elements, the function of social repre-
sentations is to  make something unusual and unknown familiar to
the patient.
Chronic obstructive pulmonary disease (COPD) and inhaled
medications do not escape these social representation systems. The
theory of social representations was first formulated by social psy-
chologist Serge Moscovici in  a paper published in  France in 1961.1
I wonder, however, if COPD is not itself also represented in doctors
who usually treat this complex disease in hospitals or in primary
health care, and if their representation is  haunted by  dogmas and
medical beliefs.
In COPD, as in many other chronic diseases, non-adherence to
medication is a  critical issue.2 Non-adherence to  inhaled therapy
 Please cite this article as: Araújo AD. Dogmas y  creencias médicas acerca de la
EPOC.  Arch Bronconeumol. 2017;53:217–218.
in  COPD has been called a  high magnitude problem and a  major
factor of therapeutic failure, but only a limited number of stud-
ies have specifically examined adherence in  patients with COPD
therapy, and most research was  conducted before the widespread
availability of inhaled medications taken once or twice daily. In
some original articles, many patient characteristics, such as the
degree of bronchial obstruction or symptoms like dyspnea, are
missing. However, it is well known that  dyspnea, fear of  dyspnea,
and feelings of vulnerability contribute to better adherence to med-
ication. Poor adherence to therapy, therefore, does not  seem to
make much sense from a clinical point of view, especially in these
very symptomatic patients with COPD Gold stage B or D. Poor
medication adherence in COPD has become a dogma that may
well not correspond to reality, at least in  patients with greater
severity, and as such remains an open issue that merits further
investigation.3
Another persistent dogma is  the belief that  once-daily medica-
tion is the best alternative for all COPD patients,4 because it is  easier
to  use and improves compliance. As effort dyspnea is the main
symptom of COPD, the most commonly recommended schedule
for bronchodilator therapy administration is early morning. Many
patients, however, experience an evening aggravation or  at least
a  fear of a  nocturnal aggravation of dyspnea. Patients use inhalers
because they feel relief from their dyspnea. As therapy in COPD is  to
some extent driven by symptoms, a  twice-daily bronchodilator reg-
imen may  be more suitable in certain patient groups, such as those
with exacerbating phenotypes or asthma-COPD overlap syndrome
(ACOS).
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The introduction of inhaled corticosteroids (ICs) to COPD ther-
apy has been widely debated in  medical and scientific communities.
Weaning from ICs  in  COPD, and 4 other important randomized
trials that evaluated the effect of IC discontinuity (COPE, COS-
MIC, INSTEAD, and WISDOM), have also created considerable
controversy.5 However, ICs in association bronchodilators have
long been a mainstay of treatment for COPD. It was only the recent
introduction of new long-acting bronchodilators, specifically devel-
oped for the treatment of COPD, and new fixed combinations
of LABA-LAMA that led to the current debate in the medical
community.6 There is  now  enough clinical evidence to challenge
the widespread use of IC  in COPD in  patients who  do not suf-
fer from exacerbations and who have not shown any benefit with
ICs.7
The science of medicine is  characterized by  its evidence-based
approach and its revisibility. As a  human activity, it is necessarily
subject to dogmas and beliefs. Whether it was the medical rep-
resentation of COPD as an inflammatory disease or the medical
belief of a real benefit to  the patient that led to the widespread
use of ICs in COPD is  still unclear. However, the medical com-
munity must wonder how real-life patients in  real-life situations
are represented in  large randomized studies (often double-
blind, placebo-controlled trials) supporting evidence-based
medicine.
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The Co-occurrence of Bronchial
Anthracofibrosis and Interstitial Lung Disease
Antracofibrosis bronquial y enfermedad pulmonar intersticial
simultáneas
To the Editor:
The term ‘bronchial anthracofibrosis’ (BAF) was  enunciated by
Chung et al.1 from Korea, when they described bronchoscopi-
cally visible anthracotic pigmentation and narrowing/obliteration
of bronchi in 28 elderly patients with significant exposure to  wood
Fig. 1. (A) High resolution computed tomography (HRCT) of the thorax [lung window] showing interlobular septal thickening along with ground glass opacities and traction
bronchiectasis in a sub-pleural distribution with multifocal narrowing of the right upper lobe bronchus (white arrow). (B) Chest high resolution computed tomography (HRCT)
(lung window) showing interlobular septal thickening along with honeycombing in a basilar and sub-pleural distribution suggestive of UIP pattern. (C) Fiberbronchoscopic
image showing anthracotic pigmentation of bronchial mucosa with narrowing and distortion of the apical segment of right upper lobe bronchus.
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smoke. The mucosal pigmentation is characteristically seen around
the branching point.
Increasing awareness of this disease has led to the clinical, radio-
logical and bronchoscopic characterisation of BAF, and its strong
association with tuberculosis, pneumonia, chronic obstructive pul-
monary disease and lung cancer have been highlighted.2 However,
the association of BAF with interstitial lung disease (ILD) has rarely
been documented. Only two reports in four patients have been
published,3,4 with only one report detailing the co-occurrence of
usual interstitial pneumonia (UIP) pattern with BAF.5 The rarity of
such a description in the literature prompted us to  report 2 female
patients who  underwent diagnostic fiberbronchoscopy (FOB) for
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